See more : SIM Technology Group Limited (2000.HK) Income Statement Analysis – Financial Results
Complete financial analysis of NKGen Biotech, Inc. Warrants (NKGNW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NKGen Biotech, Inc. Warrants, a leading company in the Biotechnology industry within the Healthcare sector.
- Tecstar Technology Co., Ltd. (3117.TWO) Income Statement Analysis – Financial Results
- Inscape Corporation (INQ.TO) Income Statement Analysis – Financial Results
- ITmedia Inc. (2148.T) Income Statement Analysis – Financial Results
- Johnson Chemical Pharmaceutical Works Co., Ltd. (4747.TWO) Income Statement Analysis – Financial Results
- Dhampur Sugar Mills Limited (DHAMPURSUG.BO) Income Statement Analysis – Financial Results
NKGen Biotech, Inc. Warrants (NKGNW)
About NKGen Biotech, Inc. Warrants
Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 77.00K | 426.00K |
| Cost of Revenue | 1.20M | 18.00K | 30.00K |
| Gross Profit | -1.20M | 59.00K | 396.00K |
| Gross Profit Ratio | 0.00% | 76.62% | 92.96% |
| Research & Development | 14.47M | 16.75M | 14.67M |
| General & Administrative | 0.00 | 7.66M | 7.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 14.08M | 7.66M | 7.59M |
| Other Expenses | 0.00 | -95.00K | -84.00K |
| Operating Expenses | 28.54M | 24.41M | 22.26M |
| Cost & Expenses | 29.75M | 24.42M | 22.29M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 745.00K | 2.31M | 1.32M |
| Depreciation & Amortization | 1.20M | 1.21M | 1.24M |
| EBITDA | -28.54M | -23.23M | -20.70M |
| EBITDA Ratio | 0.00% | -29,598.70% | -4,859.39% |
| Operating Income | -29.75M | -24.35M | -21.86M |
| Operating Income Ratio | 0.00% | -31,618.18% | -5,131.69% |
| Total Other Income/Expenses | -53.20M | -2.40M | -1.40M |
| Income Before Tax | -82.95M | -26.75M | -23.26M |
| Income Before Tax Ratio | 0.00% | -34,736.36% | -5,460.09% |
| Income Tax Expense | 7.00K | 7.00K | 5.00K |
| Net Income | -82.95M | -26.75M | -23.27M |
| Net Income Ratio | 0.00% | -34,745.45% | -5,461.27% |
| EPS | -5.38 | -4.21 | -1.08 |
| EPS Diluted | -5.38 | -4.21 | -1.08 |
| Weighted Avg Shares Out | 15.43M | 6.36M | 21.45M |
| Weighted Avg Shares Out (Dil) | 15.43M | 6.36M | 21.45M |
Source: https://incomestatements.info
Category: Stock Reports